Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 38(2): 106-111, mar.-abr. 2019. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-182393

RESUMO

Actualmente las opciones de tratamiento disponibles para el cáncer de próstata resistente a la castración metastásico (CPRCm) son diversas, pero carecemos de datos prospectivos sobre la mejor estrategia de secuenciación en estos pacientes. El dicloruro de 223Ra es el primer radiofármaco emisor de partículas alfa que ha demostrado aumento de supervivencia en pacientes con CPRCm. Este fármaco actúa selectivamente sobre el hueso, por lo que existe una ventana de oportunidad para su administración previa al desarrollo de metástasis viscerales, que debe ser tenida en cuenta a la hora de diseñar la estrategia terapéutica de estos pacientes. Es necesario, por tanto, definir los diferentes escenarios disponibles en la práctica clínica con el fin de llevar a cabo una mejor selección de pacientes y su correcta monitorización


Currently, there are several options available for the treatment of metastatic castration resistant prostate cancer (mCRPC), however evidence on the optimal treatment sequence is lacking. 223Ra is the first targeted alpha therapy that has shown an improvement in overall survival in mCRPC patients. This drug specifically targets bone lesions, so there is a window of opportunity for the administration of 223Ra previous to the development of visceral metastases. This should be taken into account to design the therapeutic strategy for mCRPC patients. It is necessary, therefore, to review the different approaches in routine clinical practice, to define best practices for patient selection and on-treatment monitoring


Assuntos
Humanos , Neoplasias de Próstata Resistentes à Castração/radioterapia , Compostos Radiofarmacêuticos/uso terapêutico , Rádio (Elemento)/uso terapêutico , Neoplasias Ósseas/secundário , Metástase Neoplásica/radioterapia , Acetato de Abiraterona/uso terapêutico , Docetaxel/uso terapêutico , Biomarcadores Tumorais/análise
2.
Rev Esp Med Nucl Imagen Mol ; 38(2): 106-111, 2019.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30711438

RESUMO

Currently, there are several options available for the treatment of metastatic castration resistant prostate cancer (mCRPC), however evidence on the optimal treatment sequence is lacking. 223Ra is the first targeted alpha therapy that has shown an improvement in overall survival in mCRPC patients. This drug specifically targets bone lesions, so there is a window of opportunity for the administration of 223Ra previous to the development of visceral metastases. This should be taken into account to design the therapeutic strategy for mCRPC patients. It is necessary, therefore, to review the different approaches in routine clinical practice, to define best practices for patient selection and on-treatment monitoring.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Próstata/radioterapia , Rádio (Elemento)/uso terapêutico , Atitude do Pessoal de Saúde , Humanos , Masculino , Oncologia , Radioisótopos/uso terapêutico
3.
Respir Med Case Rep ; 9: 8-10, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-26029620

RESUMO

We report here a 66-year-old woman diagnosed with bronchioloalveolar carcinoma of the right lung cT4N2M0. The patient was from the Philippines, had never smoked, and tested positive for an EGFR mutation. She received gefitinib as neoadjuvant therapy for two months and displayed a partial response. The tumour was resected by performing a right pneumonectomy. The residual viable tumour accounted for less than 10%. Adjuvant chemotherapy with carboplatin-taxol was administered for four cycles. Fifteen months post-surgery, two brain metastases were found. Gefitinib was prescribed, and one month later complete radiological response was assessed. The patient remains asymptomatic and without visible disease four months later. Controlled randomised trials are needed to clarify the role of these target therapies in the neoadjuvant setting.

4.
Mech Ageing Dev ; 119(1-2): 41-7, 2000 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-11040400

RESUMO

It is generally accepted that free-radical induced blood lipid peroxidation and especially peroxidized LDL play a central role in the pathogenesis of atherosclerosis and related cardiovascular disease. Moreover, recent research highlights the key contribution of apolipoprotein B (apo B) to atherogenesis as the main inductor of one of its earlier steps, i.e. macrophage proliferation. This has led us to investigate the apo B response to a very effective phenolic lipid-antioxidant, namely an hydroalcoholic extract of Curcuma longa, which according to our previous work does not show any toxic effects and decreases the levels of blood lipid peroxides, oxidized lipoproteins and fibrinogen. The present study shows that a daily oral administration of the extract decreases significantly the LDL and apo B and increases the HDL and apo A of healthy subjects. This and recent data on the increased anti-atherogenic action of the physiological antioxidant tocopherol in the presence of phenolic co-antioxidants (which eliminate the tocopheroxyl radical), justifies planned clinical research to test the usefulness of the curcuma extract as a co-antioxidant complement to standard treatments to prevent or retard atherosclerosis.


Assuntos
Apolipoproteínas A/metabolismo , Apolipoproteínas B/metabolismo , Arteriosclerose/prevenção & controle , Zingiberales/metabolismo , Adulto , Idoso , Álcoois , Feminino , Humanos , Lipoproteínas HDL/metabolismo , Lipoproteínas LDL/metabolismo , Masculino , Pessoa de Meia-Idade , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia
6.
Mech Ageing Dev ; 100(1): 17-24, 1998 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-9509391

RESUMO

There is considerable support for the concept that oxygen free radicals and related lipid peroxides play a key role in the pathogenesis of normal senescence and of age-related chronic degenerative diseases, including atherosclerosis. This has led to a great deal of interest regarding peroxidized LDL, which seems to be more atherogenic than LDL. In contrast, the relationship of total serum or plasma lipid peroxides (which also have a marked atherogenic action) with both aging and atherogenesis are not well understood. In view of the above, we have determined the level of serum lipid peroxide (expressed as thiobarbituric acid reactive substances) in a sample of 100 healthy men and women ranging in age from 20 to 70 years. Our data show that there is an age related increase in the concentration of lipid peroxide, with men showing higher or about equal values than women until about 60 years, after which age women show the higher values. Our data also suggest that in certain men and women, aging is linked to a decline in the competence of the oxyradical-detoxifying mechanisms, which results in increased serum lipid peroxidation. Further research is needed to find out if lowering the serum peroxide levels of aging subjects by diet supplementation with antioxidants will decrease that risk. An adequate intake of antioxidants seems especially indicated in post-menopausal women because of their apparent greater sensitivity to age related oxygen stress.


Assuntos
Envelhecimento/sangue , Arteriosclerose/prevenção & controle , Peróxidos Lipídicos/sangue , Adulto , Idoso , Arteriosclerose/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
7.
Arzneimittelforschung ; 45(8): 901-4, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7575758

RESUMO

The in vitro effect of Anapsos, a water based extract of the naturally occurring fern Polypodium leucotomos (calagualine), on human leukocyte fractions was investigated. Calagualine inhibited interleukin-2 secretion and concanavalin A (Con A) stimulated proliferation of T-lymphocytes in a concentration dependent manner. In contrast, a greatly enhanced secretion of IL-1 alpha, IL-1 beta and tumor necrosis factor alpha was induced suggesting a stimulation of monocytes and dendritic cells also present in this system. Endotoxin induced stimulation was excluded. Also in the absence of Con A, calagualine stimulated cytokine production. The presented data show for the first time that calagualine exerts an immunomodulating effect on leukocyte fractions, paving the way for further detailed studies related to possible clinical efficacy.


Assuntos
Adjuvantes Imunológicos/farmacologia , Leucócitos/imunologia , Plantas Medicinais/química , Citocinas/efeitos dos fármacos , Citocinas/metabolismo , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/metabolismo , Feminino , Honduras , Humanos , Técnicas In Vitro , Interleucina-2/biossíntese , Leucócitos/efeitos dos fármacos , Teste do Limulus , Ativação Linfocitária/efeitos dos fármacos , Masculino , Monócitos/efeitos dos fármacos , Monócitos/metabolismo , Extratos Vegetais/farmacologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Linfócitos T/metabolismo , Timidina/metabolismo
8.
Allergol Immunopathol (Madr) ; 23(4): 153-9, 1995 Jul-Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-8553989

RESUMO

A study of pharmacovigilance has been performed in 522 patients suffering from allergic rhinitis and/or asthma. Sensitization was due to pollens and mites in ther majority of cases. The treatment consisted in biologically standardized glycerinated allergenic extracts for specific sublingual immunotherapy (SLIT) and, major allergens were also quantified, depending on the allergenic composition. The aims of the study were to assay the effect of the SLIT in a short-and-medium-term course and to know the adverse reactions most frequently appearing, as well as the unexpected side effects that are only possible to know through the study of a numerous sample of patients. We also evaluated the factors that can modify the tolerance of the treatment, such as the onset of patient's disease and its severity. All the patients had a clinical history of, at least, two years of evolution and positive skin-prick test to the allergen/s cause of their atopic disorder. Exclusion criteria were immunotherapy in the last two years, pregnancy and those situations in which the immunotherapy is contraindicated according to the EAACI requirements. In order to carry out the daily record of the SLIT as well as the possible appearance of symptoms, two diaries were given to each patient. Tolerance was evaluated by the physician at the end of the build-up phase (3 months) and when the maintenance phase finished (5 months later). Total administered doses were 44.021, the final number of patients who registered any adverse reaction in relation with SLIT was 41 (7.9%), with a number of 67 adverse reactions that means a 0.15% over the total administered doses.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Alérgenos/uso terapêutico , Dessensibilização Imunológica , Hipersensibilidade Respiratória/terapia , Administração Sublingual , Adolescente , Adulto , Alérgenos/administração & dosagem , Alérgenos/efeitos adversos , Animais , Criança , Dessensibilização Imunológica/efeitos adversos , Feminino , Humanos , Masculino , Ácaros/imunologia , Pólen/imunologia , Vigilância de Produtos Comercializados , Estudos Prospectivos , Prurido/induzido quimicamente , Hipersensibilidade Respiratória/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA